Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Newborn screening for hereditary tyrosinaemia type 1 introduced in England

Hereditary tyrosinaemia type 1 (HT1) is a very rare genetic condition affecting about seven babies per year in the UK. It prevents the body from breaking down a substance called tyrosine found in food. This leads to the build-up of toxic levels of substances in the blood that can damage the liver, kidneys, and nervous system.

UK National Screening Committee carried out the review in 2022 and recommended screening for HT1. 

In March 2024, the English government endorsed the UK National Screening Committee's recommendation to introduce newborn screening for HT1. Testing for HT1 will be added to the NHS Newborn Blood Spot Screening Programme in England.

See more details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.